cjc 1295 & ipamorelin blend CJC-1295 + – Growth Hormone 99%+ Pure CJC-1295 No DAC + Ipamorelin

The trial failed to show a difference (56) without being powered to address the broader effect JAK inhibition may have on disease activity

10.1152/physrev.00003.2008 14 FengW.ZhuL.ShenH

doi: 10.1101/cshperspect.a002899 91 FerreriDMVincentPA

mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation

Soil salinity: A global threat to sustainable development